openPR Logo
Press release

Key Developments in Global Opioid-induced Constipation (OIC) Treatment Market

04-01-2016 02:28 PM CET | Health & Medicine

Press release from: Transarency Market Research

Key Developments in Global Opioid-induced Constipation (OIC)

Transparency Market Research has published a new market report titled, “Opioid Induced Constipation Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023”. According to the report, the global opioid induced constipation treatment market was valued at US$0.4 bn in 2014 and is anticipated to expand at a CAGR of 31.2% from 2015 to 2023 to reach US$4.8 bn by 2023.

Read More: http://www.transparencymarketresearch.com/opioidinduced-constipation-treatment-market.html

The report provides detailed analysis of current and emerging drugs for opioid induced constipation treatment, and the market is estimated based on type of drug class and dosage form of the drugs. Drug classes include mu-opioid receptor antagonist, chloride channel activator, and others based on their mechanism of action. Based on dosage form of drugs, the market has been segmented into solid, semi-solid, and liquid.

The chloride channel activator segment accounted for the largest share of the opioid induced constipation treatment market in 2014 due to first approval and launch of Amitiza in major countries. However, mu-opioid receptor antagonist was the fastest growing segment due to recent launch of the new drug Moventik and presence of pipeline drugs (naldemedine and other early stage drugs). Mu-opioid receptor antagonist drugs target the root cause of constipation by acting on specific peripheral opioid receptors, which revert the opioid action without affecting opioids analgesic action. Presently, Amitiza is the only available drug that belongs to the chloride channel activator class. However, mu-opioid receptor antagonist class consists of Moventik (AstraZeneca), Relistor (Valeant Pharmaceuticals, Inc.), and Naloxone. Additionally, naldemedine is in the late stage clinical trial. The drug is investigational, oral, mu-opioid receptor antagonist and is expected to launch in mid-2016. In August 2015, Shionogi’s naldemedine met primary and secondary endpoints in phase III clinical trial (COMPOSE II) to treat opioid induced constipation. Linaclotide is another potential drug, which is currently in phase II clinical trial. Phase I clinical trial (KODIAK16) is underway to assess the efficacy and safety of naloxegol in the treatment of opioid induced constipation in pediatric patients. The trial is expected to be completed in November 2017. Hence, launch of pipeline drugs during the forecast period is expected to boost the growth the PAMORA segment.

The others segment includes Resolor (prucalopride), bulking agents (cellulose and psyllium), stool softeners (docusate), laxatives, and osmotic agents (lactulose, sorbitol, and polyethylene glycol). Major players in this segment are Boehringer Ingelheim GmbH and C.B. Fleet Company, Inc. Traditional laxatives are not legally approved for the treatment of opioid induced constipation. However, low cost of therapy, high awareness, and easy access to medicines accounted significant share of the opioid induced constipation treatment market. For instance, monthly cost of standard laxative therapy ranges from US$ 6 to US$ 80. However, monthly cost of Amitiza ranges from US$ 300 to US$ 400 and from US$ 600 to US$ 1000 for Relistor. Asia Pacific, Latin America, and Middle East & Africa are the major consumers of traditional medicines used to treat opioid induced constipation due to easy access, low cost, and less awareness about targeted therapy.

Request A Sample Of This Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=6862

Furthermore, based on dosage form, the market has been segmented into solid, semi-solid, and liquid. The solid dosage form segment accounted for the largest share of the market in 2014. The segment is expected to maintain its leadership position during the forecast period. This is due to high patient compliance and launch of new drugs in solid form such as capsules, tablets, and pills. The semi-solid and liquid dosage form segments accounted for small shares of the market.

The number of players operating in the opioid induced constipation treatment market is small, while demand for the therapy is high. Major players operating in the global opioid induced constipation treatment market are AstraZeneca plc, Takeda Pharmaceutical Company Limited, Abbott Laboratories, Valeant Pharmaceuticals International, Inc., Bayer AG, C.B. Fleet Company, Inc., Boehringer Ingelheim GmbH, Daewoong Co. Ltd., and Cosmo Pharmaceuticals. Acquisitions and collaborations among major companies to commercialize OIC medicines are expected to boost the market during the forecast period. For instance, in March 2015, AstraZeneca and Daiichi Sankyo signed a co-commercialization agreement for Moventik in the U.S. In addition, in October 2014, Takeda and Sucampo entered into global license, development, and commercialization agreement for Amitiza. Hence, strategic agreements between companies are expected to drive the opioid induced constipation treatment market during the forecast period from 2015 to 2023.

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services.

Mr. Sudip S
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email:Â sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Key Developments in Global Opioid-induced Constipation (OIC) Treatment Market here

News-ID: 329693 • Views: 339

More Releases from Transarency Market Research

Advanced Wound Care Management Market projected to expand at a CAGR of 5.8% from …
Transparency Market Research (TMR) has published a new report titled, “Advanced Wound Care Management Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global advanced wound care management market was valued at US$ 8.5 Bn in 2016 and is projected to expand at a CAGR of 5.8% from 2018 to 2026. Surge in incidence of chronic wounds and trauma cases is anticipated
Home Care Services Market Overview, Global Demand and Industry Outlook 2020-2030
Global Home Care Services Market: Overview Home care services encompass a wide variety of services offered to individuals who cannot take care of themselves. These can be offered temporarily till the individual is independently functional or as end of life care for elderly people. Contrary to popular opinion, home care can be provided to individuals from any age group who are recovering from an ailment. Any form of health care provided
Cannabis Testing Market set to witness surge in demand over the forecast period …
Cannabis Testing Market: Overview Cannabis testing involves use of several medical devices to detect the quality of cannabis. This helps to identify the applications of cannabis for several medical purposes. Previously, both cultivation and sales of cannabis were ban across the globe until 1900. Now many countries are recognizing the benefits of cannabis for medicinal purposes and revoking their ban. This is
Female Stress Urinary Incontinence Treatment Device Market set to witness surge …
Global Female Stress Urinary Incontinence Treatment Device Market – Overview Female stress urinary incontinence can be segmented in two ways – urethral hypermobility and intrinsic sphincter deficiency (ISD). For women suffering from urethral hypermobility, slings are the most common treatment method. However, the patient may still end up with stress urinary incontinence because of ISD. Enlarged prostate, excessive urine formation, Parkinson’s syndrome, and muscle damage are some of the key factors

All 5 Releases


More Releases for Opioid

Analgesics Market Driven by Growing Opioid and Non-Opioid Medicine Sales
The application of opioids for the treatment of pain due to cancer, surgery, injury and trauma makes it a bright prospect in the augmentation of analgesics market. Along with opioid drugs, non-opioid is expected to underpin the analgesics market. Prominent companies are grappling to invest in research and development to augment non-opioid drugs through the application of innovative drug delivery approaches which will help in alleviating pain for considerably longer
Opioid Induced Constipation Treatment Market: Mu-opioid Receptor Antagonists to …
Takeda Pharmaceuticals Company, Ltd., with its approved drug Amitiza, holds a majority share in the global market for opioid induced constipation treatment. In 2014 the top three players - Takeda, Valeant Pharmaceuticals International, Ltd., and Boehringer Ingelheim – operated on a collective share of 91.8% of the global market. This is a highly consolidated market but with a large scope for the prominent players to penetrate regions other than North
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
Opioid Induced Side Effects Treatment Market
Opioids are the class of drug that include strong pain relievers and illegal drugs such as heroin and illicit pain relievers for example hydrocodone, oxycodone, morphine and fentanyl. Also they are available legally on prescription. These drugs interact with opioid receptors on nerve cells in body and are well known for the management of acute pain and cancer related pain among patients of all age group. However, opioid drugs use in
Opioid Induced Side Effects Treatment Market
Opioids are the class of drug that include strong pain relievers and illegal drugs such as heroin and illicit pain relievers for example hydrocodone, oxycodone, morphine and fentanyl. Also they are available legally on prescription. These drugs interact with opioid receptors on nerve cells in body and are well known for the management of acute pain and cancer related pain among patients of all age group. However, opioid drugs use in
Opioid Induced Constipation Treatment Market
Opioids are medications that work on opioid receptors in order to generate morphine-like effects. These are mainly used therapeutically to relieve pain and are often abused by individuals addicted to them. Opioids comprises opiates, a conventional name that points to drugs that are derivatives of opium, including morphine. Constipation means bowel actions that are sporadic or hard to go by. The fecal matter is often dry and hard. Some of